98%
921
2 minutes
20
Stereotactic radiosurgery is a widely used treatment modality for brain metastases, particularly in cases with a limited number and volume of lesions. While adaptive strategies have gained prominence in the stereotactic treatment of extracranial, their application in intracranial SRS remains largely unexplored. This case study presents a 45-year-old female with multiple brain metastases and significant perilesional edema, treated with fractionated stereotactic radiotherapy. Due to tumor displacement during the treatment course, adaptive SRS was implemented after the third fraction, utilizing an updated MRI scan to account for changes in tumor volume and midline shift. The total GTV decreased by 34.2 %, and five lesions were found to be partially outside the prescribed treatment target. Based on this MRI, an offline adaptive SRS plan was generated, and the remaining two fractions were delivered according to the updated plan. This case underscores the potential for significant changes in target volume and spatial displacement during FSRT in patients with brain metastases exhibiting extensive edema and emphasizes the importance of mid-treatment imaging and the potential role of offline adaptive SRS strategies in managing intracranial tumors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246714 | PMC |
http://dx.doi.org/10.1016/j.ctro.2025.101000 | DOI Listing |
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.
BMJ Health Care Inform
September 2025
Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
Objectives: The objectives were to examine the associations between accelerometer-measured circadian rest-activity rhythm (CRAR), the most prominent circadian rhythm in humans and the risk of mortality from all-cause, cancer and cardiovascular disease (CVD) in patients with cancer.
Methods: 7456 cancer participants from the UK Biobank were included. All participants wore accelerometers from 2013 to 2015 and were followed up until 24 January 2024, with a median follow-up of 9.
Radiother Oncol
September 2025
Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. Electronic address:
Background: In recent years, intraoperative radiotherapy (IORT) with low-energy X-rays is emerging as an alternative to postoperative stereotactic radiotherapy (SRT) of the resection cavity in patients with resectable brain metastases (BMs).
Methods: We performed a systematic review of the MEDLINE, Embase, and Scopus databases, including all original articles on IORT for resectable BMs from 2015 to 2025. Data on safety, local control, and survival outcomes were collected.
Radiother Oncol
September 2025
Amsterdam UMC, Location University of Amsterdam, Department of Neurosurgery, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Background And Purpose: Staged Gamma Knife radiosurgery (SGKRS) delivers high-dose radiotherapy to large brain metastases (BM) in two or three fractions with a time interval of several weeks. Various systemic treatments have also demonstrated favorable intracranial responses. Therefore, the outcome of patients undergoing radiosurgery and systemic treatment for large BM is of high interest but unknown.
View Article and Find Full Text PDFStem Cell Reports
September 2025
Laboratory of Neural Stem Cells and Functional Neurogenetics, Farmington, CT 06030, USA; Departments of Neuroscience, Neurology, Genetics and Genome Sciences, UConn Health, Farmington, CT 06030, USA. Electronic address:
Intratumoral heterogeneity in glioblastoma is thought to underlie its remarkable ability to recur and resist therapies. Its origins, however, remain unknown. In this issue, Liu et al.
View Article and Find Full Text PDF